Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
| Status: | Archived |
|---|---|
| Conditions: | Ocular, Diabetes |
| Therapuetic Areas: | Endocrinology, Ophthalmology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2007 |
| End Date: | February 2012 |
Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)
The purpose of this trial is to treat Proliferative Diabetic Retinopathy (PDR) induced
rubeosis expeditiously prior to cataract surgery, and to reduce the bleeding complications
encountered during cataract surgery.
Patients will receive 3 monthly intravitreal injections of 0.5 mg ranibizumab in the study
eye. All subjects will undergo cataract surgery after the first injection. After the 3rd
monthly injection, the follow-up is bi-monthly for the first year of enrollment;
intervention would be ranibizumab and PRP laser if rubeosis recurred. The safety visits
would be at 18 and 24 months follow-up.
We found this trial at
1
site
Click here to add this to my saved trials
